Skip to main content

Search

Reset all filters
109 Result(s)
Sort by

Patients in Focus

Patients in Focus

Boehringer Ingelheim RCV provides over six million patients with innovative therapies. Ensuring that the patients’ needs at every stage are met precisely is of decisive importance.
Testing New Treatments for NF1

Testing New Treatments for NF1

The Medical University of Vienna and Boehringer Ingelheim have taken an innovative approach to the development of ways of treating NF1-associated tumors.
Reimagining digital healthcare worldwide

Reimagining digital healthcare worldwide

How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, nearly half of the world's population lacks access to basic health care.
Partnering

Partnering

We are convinced that diversity and exchange in science give birth to innovations. For this reason, partnerships are an important component of our innovation strategy.
More Potential: Overview

More Potential: Overview

Society continues to face challenges ranging from health to education, work prospects, living conditions, inequalities and poverty, often impacting vulnerable communities the most.
Schizophrenia in real life

Schizophrenia in real life

Through these real-life stories, discover the eye-opening reality of life with schizophrenia.
Our Commitment

Our Commitment

Humanity faces great challenges. We believe that we can always do more - for ourselves and for future generations.
Our Expectations

Our Expectations

We are committed to exemplary ethical and professional conduct both within the company and from our suppliers.
Who we are

Who we are

The Boehringer Ingelheim Regional Center Vienna (RCV for short) bears business responsibility for more than 30 countries in Central and Eastern Europe and Central Asia.